CC
PRLD icon

Corton Capital’s Prelude Therapeutics PRLD Stock Holding History

Corton Capital’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,586
Closed -$81K – 346
2022
Q2 		$81K Buy
15,586
+4,668
+43% +$23.8K 0.08% 294
2022
Q1 		$75K Buy
+10,918
New +$99.9K 0.03% 398

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Corton Capital's PRLD Position: Q3 2022 in Review

Corton Capital sold out of Prelude Therapeutics (PRLD) in Q3 2022, closing a stake of 15,586 shares — an estimated $81K sold.

Corton Capital first reported a position in PRLD in Q1 2022 and held it in 2 quarters. The position peaked at $81K in Q2 2022. 53 funds tracked by Wall St. Rank hold PRLD as of Q3 2022.

  • Corton Capital reported no remaining Prelude Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Corton Capital sold 15,586 Prelude Therapeutics shares in Q3 2022, an estimated $81K.
  • Corton Capital first reported a position in Prelude Therapeutics in Q1 2022 and held it in 2 quarters.
  • Corton Capital's Prelude Therapeutics position peaked at $81K in Q2 2022.
  • 53 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2022.

Based on Corton Capital's 13F filing for Q3 2022, filed 14 Nov 2022.